

1

2 **Deoxycholic acid activates colonic afferent nerves via 5-HT₃**

3 **receptor dependent and independent mechanisms**

4

5 **Running title: Deoxycholic acid activates colonic afferents**

6

7 **Yang Yu^{1*}, Egina C. Villalobos-Hernandez^{1*}, Sabindra Pradhananga¹, Corey C.**
8 **Baker¹, Christopher Keating², David Grundy², Alan E. Lomax¹, and David E.**
9 **Reed¹**

10

11 ¹Gastrointestinal Diseases Research Unit, Queen's University, Kingston, Ontario,
12 Canada

13 ²Department of Biomedical Science, University of Sheffield, Sheffield, UK

14

15 *Yang Yu and Egina C. Villalobos-Hernandez contributed equally to this work.

16

17 **Address for correspondence:**

18

19 **David Reed**

20 Gastrointestinal Diseases Research Unit,

21 Kingston General Hospital

22 Queen's University

23 76 Stuart St.

24 Kingston, ON,

25 K7L 2V7, Canada.

26 Tel. +1 6135496666x3344

27 Email: david.reed@queensu.ca

28

29

30 **Abbreviations**

31 5-HT (5-hydroxytryptamine), DCA (deoxycholic acid), DRG (dorsal root ganglion), EC
32 (enterochromaffin), FXR (farnesoid X receptor), GLP-1 (glucagon-like peptide-1),
33 GPBAR1/TGR5 (G protein-coupled bile acid receptor), HT (high threshold), IBS
34 (irritable bowel syndrome), LT (low threshold), NG (nodose ganglion), RMP (resting
35 membrane potential), TRPA1 (transient receptor potential ankyrin receptor).

36

37 **Abstract**

38 Increased bile acids in the colon can evoke increased epithelial secretion resulting in
39 diarrhea but little is known whether colonic bile acids contribute to abdominal pain.
40 This study aimed to investigate the mechanisms underlying activation of colonic
41 extrinsic afferent nerves and their neuronal cell bodies by a major secondary bile acid,
42 deoxycholic acid (DCA). All experiments were performed on male C57BL/6 mice.
43 Afferent sensitivity was evaluated using *in vitro* extracellular recordings from
44 mesenteric nerves in the proximal colon (innervated by vagal and spinal afferents) and
45 distal colon (spinal afferents only). Neuronal excitability of cultured dorsal root
46 ganglion (DRG) and nodose ganglion (NG) neurons was examined with perforated
47 patch clamp. Colonic 5-HT release was assessed using ELISA, and 5-HT
48 immunoreactive enterochromaffin (EC) cells were quantified. Intraluminal DCA
49 increased afferent nerve firing rate concentration-dependently in both proximal and
50 distal colon. This DCA-elicited increase was significantly inhibited by a 5-HT₃
51 antagonist in the proximal colon but not in the distal colon, which may be in part due to
52 lower 5-HT immunoreactive EC cell density and lower 5-HT levels in the distal colon
53 following DCA stimulation. DCA increased the excitability of DRG neurons, whereas it
54 decreased the excitability of NG neurons. DCA potentiated mechanosensitivity of high
55 threshold spinal afferents independent of 5-HT release. Together, this study suggests
56 that DCA can excite colonic afferents via direct and indirect mechanisms but the
57 predominant mechanism may differ between vagal and spinal afferents. Furthermore,
58 DCA increased mechanosensitivity of high threshold spinal afferents and may be a
59 mechanism of visceral hypersensitivity.

60

61

62 **Key words:**

63 **Bile acid, spinal afferent, vagal afferent, 5-HT, hypersensitivity**

64

65

66

67 **New & Noteworthy**

- 68 • DCA directly excites spinal afferents, and to a lesser extent, indirectly via
69 mucosal 5-HT release.
- 70 • DCA potentiates mechanosensitivity of high threshold spinal afferents
71 independent of 5-HT release.
- 72 • DCA increases vagal afferent firing in proximal colon via 5-HT release but
73 directly inhibits the excitability of their cell bodies.

74

75

76

77 **Introduction**

78 Bile acids are classically known for their roles in facilitating the digestion and
79 absorption of dietary lipids. Primary bile acids are synthesized from cholesterol and
80 conjugated with glycine or taurine in the liver. They are stored in the gall bladder, and
81 released into the small intestine upon digestion of a meal. Most bile acids are
82 reabsorbed by active transport in the ileum, although a small proportion, 5%, enters the
83 colon where bacteria deconjugate and dehydroxylate primary bile salts to form
84 secondary bile acids, that can be partly passively absorbed into the enterohepatic
85 circulation (7). Deoxycholic acid (DCA), a secondary bile acid converted from cholic
86 acid, is normally the predominant colonic bile acid (26).

87

88 Emerging evidence has suggested that bile acids also have complex hormonal actions
89 both within and outside the intestinal tract, particular through the farnesoid X receptor
90 (FXR) and G protein-coupled bile acid receptor (GPBAR1), also known as TGR5 (29).
91 FXR is a nuclear receptor that mediates the genomic actions of bile acids and plays a
92 key role in activating pathways that maintain bile acid homeostasis (10). TGR5 is a
93 transmembrane receptor that couples to G α s and cAMP signaling pathways. TGR5 has
94 been implicated in mediating the actions of bile acids on secretion, motility, sensory
95 transduction and inflammation (7).

96

97 Disruptions in the synthesis, excretion and recycling of bile acids are implicated in the
98 onset of many diseases of the intestine, its accessory organs and beyond (18).

99 Postprandial bile acid concentration is approximately 10 mM in human proximal small
100 intestine, 2 mM in the distal ileum, and 0.6 mM in the cecum (17). Bile acids at high

101 physiological concentrations cause oxidative stress, DNA damage, apoptosis and cancer
102 (31). Elevated levels of bile acids in the colon may also have profound influence on
103 epithelial function and motility, including increased Cl^- secretion, enhanced
104 permeability and increased intestinal transit (18), and this may have important
105 implications in GI disorders. For example, increased bile acid delivery to the colon is
106 observed in a subpopulation of irritable bowel syndrome with predominant diarrhea
107 (IBS-D) patients; this is associated with altered bowel movements and accelerated
108 colonic transit time, implying a partial mechanism for symptom generation in non-
109 constipated IBS patients (4, 34, 39).

110

111 Previous work has shown that DCA can directly excite dorsal root ganglion (DRG)
112 neuron cell bodies via a TGR5-dependent mechanism (1), suggesting a potential role for
113 bile acid signaling in visceral pain. However, *in vivo* studies examining pain signaling
114 via bile acids have revealed conflicting results. For example, DCA instillation into the
115 rat colon for 3 consecutive days induced mild inflammation and persistent visceral
116 hyperalgesia (42). In another study using *in vivo* afferent recordings of pelvic nerves, a
117 mixture of sodium cholate and DCA increased baseline firing rate but
118 mechanosensitivity remained unaltered (40). Conversely, while intraplantar injection of
119 bile acids in mice caused inflammation, it also resulted in analgesia to mechanical
120 stimulation independent of inflammation (1). Discrepancies in these *in vivo* studies
121 highlight the need for *in vitro* studies at the level of primary sensory nerve terminals
122 within the intact colon to examine mechanisms of neural signaling by bile acids in the
123 distal GI tract. To achieve this, we studied two regions of the colon, the proximal colon,
124 innervated by a combination of vagal and spinal afferent nerves, and the distal colon

125 that is predominantly spinal innervation (6). This allowed us to discriminate between
126 bile acid modulation of spinal and vagal afferent pathways.

127

128

129 **Material and methods**

130 **Animals and ethical approval**

131 All experiments were approved by Queen's University Animal Care Committee, in
132 accordance with the guideline of the Canadian Council for Animal Care. Male C57BL/6
133 mice (body weight 22-25 gm) were purchased from Charles River Laboratories. They
134 were housed individually under a standard light-dark cycle (lights on: 7 am, lights off: 7
135 pm) with free access to food and water. Mice were euthanized by isoflurane inhalation
136 followed by cervical dislocation.

137

138 Human bile was obtained from 3 patients undergoing endoscopic retrograde
139 cholangiopancreatography for removal of choledocholithiasis at Kingston Health
140 Sciences Centre with informed consent. Experimental procedures were approved by
141 Queen's University Human Ethics Committee.

142

143 **Extracellular afferent nerve recording**

144 The proximal colon was defined as the first 3 cm segment of colon immediately after
145 the cecum. The proximal colon was also distinguished from the distal colon by the
146 presence of distinct mucosal folds that are easily seen through the wall of the proximal
147 colon. After identification of the superior mesenteric artery that enters the proximal end
148 of the colon, we isolated the nerve associated with this artery. The distal colon was
149 defined as a 3 cm segment immediately proximal to the pelvic brim; this segment is
150 supplied by the inferior mesenteric artery that branches from the abdominal aorta. The
151 nerve associated with this artery was isolated proximal to the inferior mesenteric
152 ganglion. This classification is similar to a previous study (13). Nerve activity of

153 colonic afferents was recorded as previously described (9). Segments of proximal or
154 distal colon were placed in an organ bath continuously superfused with gassed (5% CO₂
155 and 95% O₂) Krebs buffer (composition, in mM: NaCl, 118.4; NaHCO₃, 24.9; MgSO₄,
156 1.2; KH₂PO₄, 1.2; glucose, 11.7; CaCl₂, 1.9) at 34°C. Preparations were cannulated at
157 both ends with one end connected to an infusion pump to allow continuous perfusion of
158 Krebs solution (0.2 mL/min) while the other end was connected to a pressure transducer
159 (NL108, Digitimer, Welwyn Garden City, UK). Ramp distention was applied by closing
160 the outflow drain of the preparation until the pressure reached 60 mmHg. Nerve bundles
161 were identified in the mesentery and drawn into a glass suction electrode attached to a
162 Neurolog headstage (NL100, Digitimer). Afferent nerve signals were amplified
163 (NL104), filtered (NL125 band pass filter) and recorded on a computer via a Micro
164 1401 interface and Spike 2 software (Version 7, Cambridge Electronic Design,
165 Cambridge, UK). Krebs contained the L-type calcium channel blocker nifedipine (3 μM)
166 and the muscarinic acetylcholine receptor antagonist atropine (5 μM) to suppress
167 smooth muscle activity, as well as the cyclooxygenase inhibitor indomethacin (3 μM) to
168 suppress potential inhibitory actions of endogenous prostaglandins (33).

169

170 DCA was applied either intraluminally (0.2 ml/min) or into the bath (10 ml/min), and
171 granisetron (a selective 5-HT₃ antagonist, 1 μM) (37) was applied into both the bath and
172 lumen 15 minutes prior to DCA. Baseline afferent nerve firing frequency was
173 determined during a 120-second period just prior to application of DCA. The effect of
174 intraluminal DCA on baseline firing was calculated as a ratio of increased baseline
175 firing frequency 15 minutes after DCA administration compared to control baseline.
176 Response to bath-applied DCA was analysed similarly but a 30-second period at the

177 peak was used for analysis. The afferent nerve response to ramp distention was assessed
178 as the increase in firing rate with increased intraluminal pressure using a custom-made
179 script in Spike2. To compare distention response within the same preparations, firing
180 frequency was normalized to the peak firing rate of the control distention. Single unit
181 analysis was performed offline using the spike sorting function of Spike2 to
182 discriminate the afferent nerve activity of individual units. Based on their sensitivity to
183 ramp distention, afferent units were classified into two subpopulations, low threshold
184 (LT) and high threshold (HT), with a cut-off threshold at 15 mmHg. This cut-off
185 threshold is in keeping with previous studies in the small intestine and colon (9, 11, 28).
186 A unit was considered as responding to DCA if the afferent firing frequency increased
187 or decreased by 20% from baseline.

188

189 **5-HT release assay**

190 A 1cm segment of proximal and distal colon from each mouse were placed in ice-cold
191 Krebs solution. Segments were cut open and pinned flat with mucosa up in Sylgard-
192 coated wells. Tissue was incubated with the serotonin reuptake inhibitor fluoxetine
193 (1 μ M) in Krebs solution (1 mL) at 37 °C for 10 minutes and supernatants were then
194 collected. Following a brief rinse, the same tissue was incubated in 1mM DCA plus
195 1 μ M fluoxetine (1 mL) at 37 °C for 10 minutes. Supernatants were then collected. The
196 wet weight of the tissue was recorded. The concentration of 5-HT in the supernatants
197 was measured using an immunoassay kit (Beckman Coulter, IM1749, Indianapolis, IN,
198 US) in accordance with the manufacturer's instructions. The concentration of 5-HT was
199 normalized to the tissue weight.

200

201 Immunohistochemistry

202 Segments of proximal and distal colon were fixed overnight at 4°C in 4%
203 paraformaldehyde dissolved in 0.1 M phosphate-buffered saline (PBS), followed by 3
204 times wash with PBS. Fixed specimens were cryo-protected in 30% sucrose/PBS
205 overnight, embedded in optimal cutting temperature (OCT) compound (Wolf Labs,
206 York, UK), and sectioned at 10 µm in a cryostat (Bright Instrument, OTF5000,
207 Huntingdon, UK). Slides with sections were incubated with 5% goat serum/ PBS for 20
208 minutes to block non-specific binding, and then incubated overnight with a rabbit anti-
209 serotonin antibody previously validated in mice (24, 36) (1:50; AbD Serotec, AHP522,
210 Kidlington, UK) at 4°C, followed by PBS rinse and 2-hour incubation with a goat anti-
211 rabbit secondary antibody conjugated to Cy3 (1:400; Jackson ImmunoResearch, West
212 Grove, PA, USA) at room temperature. Slides were mounted using Vectashield
213 mounting medium with DAPI (Vector Laboratories, Peterborough, UK). A negative
214 control was performed by omitting the primary antibody; this abolished
215 immunofluorescence. When acquiring images, sections were oriented by aligning the
216 muscularis mucosae to the bottom. Ten random images from ten sections of each
217 specimen were acquired under 20× objective lens using an Olympus ColourView II
218 digital camera for offline quantification. The number of enterochromaffin (EC) cells
219 was counted in a blinded fashion. Since the transverse mucosal folds were much longer
220 in the proximal colon, EC cell density was expressed as cells per unit area of mucosa
221 (measured using ImageJ 1.43u; National Institutes of Health, Bethesda, MD, USA).

222

223 Perforated patch clamp recording

224 Dorsal root ganglion (DRG)(T9-T13) and nodose ganglion (NG) neurons were isolated
225 as previously described (9, 38). Following overnight culture, coverslips containing
226 isolated neurons were placed in a recording chamber on an inverted microscope and
227 superfused with external solution containing (in mM): NaCl 140, KCl 5, MgCl₂ 1,
228 CaCl₂ 2, HEPES 10 and glucose 10, pH 7.4 with NaOH. While we did not perform
229 retrograde labelling to specifically identify colon projecting DRG neurons, only small-
230 diameter DRG neurons (≤ 30 pF) were selected, as they are putative nociceptors. Patch
231 electrodes were pulled from Premium Custom 8520 Patch Glass (Warner Instruments)
232 and filled with an internal solution containing (in mM): K-gluconate 110, KCl 30,
233 MgCl₂ 1, CaCl₂ 2, HEPES 10, pH 7.25 with KOH. Amphotericin B (240 μ g/ml) was
234 added to the pipette solution. Neuronal excitability was assessed by determining
235 rheobase, the minimum amount of current required to elicit an action potential. Input
236 resistance was determined by the hyperpolarizing response to current step from 0 to -10
237 pA. These parameters were measured again after 10-min superfusion of vehicle or DCA
238 on the same neurons. Junction potential was calculated as 12 mV and the resting
239 membrane potential was adjusted accordingly.

240

241 **Drugs and compounds**

242 Sodium deoxycholate (D6750) and fluoxetine hydrochloride (F132) were purchased
243 from Sigma-Aldrich, and granisetron (21239) was obtained from Cayman Chemical.
244 Sodium deoxycholate was made fresh in distilled water and diluted to their final
245 concentration in Krebs buffer (with a final pH at 7.5) immediately prior to application in
246 afferent recordings. DCA stock was diluted in the external solution in patch clamp

247 recordings. Fluoxetine and granisetron were prepared as stock solution, kept frozen at -
248 20°C and diluted to their final concentration prior to application.

249

250 **Data analysis and statistics**

251 All data are expressed as means \pm SD unless otherwise stated. Significant difference
252 was determined by Student's t-test (two-tailed), one or two-way ANOVA with
253 Bonferroni test as appropriate using GraphPad Prism 6. N refers to number of animals,
254 and n indicates number of cells or afferent units. $P < 0.05$ was considered significant.
255 Significance indicator was defined as: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

256

257

258

259 **Results**

260 **DCA increased baseline afferent firing in mouse proximal and distal colon**

261 DCA is a secondary bile acid that encompasses a significant proportion of the colonic
262 bile acid pool (39). Therefore, we examined the effect of DCA on colonic afferent nerve
263 firing. In the proximal colon, increase in baseline firing in response to DCA of LT
264 afferents was small and not statistically significant (Fig. 1A, $P=0.176$, one-way
265 ANOVA with Bonferroni test, $N=4, 5$ and 10 for $100, 300 \mu\text{M}$ and 1 mM), whereas
266 DCA augmented HT afferent firing in a concentration-dependent manner with a
267 significant change observed with 1 mM (Fig. 1C, $P<0.01$). It is generally accepted that
268 HT afferents are almost exclusively spinal afferents as opposed to vagal afferents (6),
269 and so we examined the response of afferent nerves in the distal colon as it is innervated
270 predominantly by spinal afferents. Although the increase in LT afferent firing rate was
271 not statistically significant (Fig. 1B, $P=0.091$, $N=6$ for both $100 \mu\text{M}$ and 1 mM), a
272 significant change was observed for 1 mM DCA in HT afferents in distal colon (Fig. 1D,
273 $P<0.05$). In the proximal colon, 46% of units ($n=45$) were LT afferents and of these 62%
274 showed increased baseline firing frequency in response to 1 mM DCA, while 47% units
275 were HT afferents with 81% responsive to DCA (Fig. 1E). In the distal colon, 44% of
276 afferents ($n=27$) were LT units and 58% of these responded to DCA, while 41% units
277 were HT afferents and 46% were DCA responders (Fig. 1F). The proportion of
278 mechanically insensitive (MI) units was very low and thus were not included in the
279 analysis of DCA response. Intraluminally-applied human bile (1:10 diluted in Krebs) in
280 mouse proximal colon significantly increased baseline afferent firing rate with a similar
281 response profile to 1 mM DCA (Supplementary Fig. 1).

282

283 **Intraluminal administration of DCA activated afferent nerves indirectly via 5-HT**
284 **release**

285 Bath-applied DCA (1mM) elicited an immediate increase in baseline afferent nerve
286 firing frequency, while intraluminal administration evoked a slow and smaller increase
287 in baseline firing (Fig. 2A). Given the short time for bath perfusion (1 min), this is most
288 likely due to direct actions of DCA on the afferent endings. Considering the delayed
289 response to intraluminal application and evidence that bile acid induces release of 5-HT
290 (2, 25, 35), we hypothesized that intraluminal application of DCA increased afferent
291 discharge indirectly via mucosal 5-HT release. In agreement with this, pre-treatment
292 with granisetron (1 μ M), a 5-HT₃ antagonist, did not change the afferent response to
293 bath-applied DCA (1mM) in both proximal (Fig. 2B left, $P=0.075$, paired t-test, $N=5$)
294 and distal colon (Fig. 2C, $P=0.405$, $N=5$). Since nerve activity did not return to baseline
295 after bath application of DCA in most proximal colon recordings, we reversed the order
296 of treatments to confirm that granisetron did not inhibit afferent responses to bath-
297 applied DCA (Fig. 2B right, $P=0.092$, paired t-test, $N=5$). However, granisetron
298 significantly inhibited the afferent response to intraluminal application of DCA in the
299 proximal colon (Fig. 2C, $P<0.01$, paired t-test, $N=5$), and reversal of the order of
300 treatments confirmed the inhibitory effect of granisetron (Fig. 2D, $P<0.05$, $N=5$).
301 However, in the distal colon, while the response to intraluminal application of DCA was
302 reduced by granisetron, this was not significant (Fig. 2E, $P=0.266$, paired t-test, $N=8$),
303 although 5 out of 8 preparations showed a smaller response in the presence of
304 granisetron. The percent of inhibition on afferent response to DCA by granisetron was
305 significantly lower in the distal colon compared to proximal (Fig. 2F, $P<0.05$, unpaired

306 t-test). Since distention itself can evoke 5-HT release from the mucosa (5) that may
307 impact the availability of mucosal 5-HT to be released upon repeated applications of
308 DCA, we did not perform distention during these experiments and thus were unable to
309 define the proportion of LT and HT units attenuated by granisetron.

310

311 **DCA stimulated 5-HT release in the proximal and distal colon**

312 Given the effect of granisetron on afferent response to DCA, we examined the effect of
313 DCA on 5-HT release. Compared to basal release, 1 mM DCA increased 5-HT release
314 in both proximal (Fig. 3A, $P<0.05$, paired t-test, $N=5$) and distal colon (Fig. 3B, $P<0.01$,
315 paired t-test, $N=5$). Basal 5-HT release in the proximal colon was higher compared to
316 the distal colon (Fig. 3C, $P<0.01$, unpaired t-test). Absolute 5-HT release upon DCA
317 stimulation was greater in the proximal colon than the distal colon (Fig. 3D, $P<0.05$,
318 unpaired t-test), although the net increase (subtracted by basal release) was not
319 significantly different (0.5 ± 0.1 vs. 0.5 ± 0.1 nM/mg, $P=0.897$).

320

321 We next examined the density of EC cells in the proximal and distal colon with an anti-
322 serotonin antibody. 5-HT immunoreactive EC cells were identified in the epithelium
323 lining in both proximal and distal colon (Fig. 3E). Similar to the greater 5-HT release
324 observed in the proximal colon, EC cell density was greater in the proximal colon
325 compared to the distal colon (Fig. 3F, $P<0.01$, unpaired t-test, $N=5$ for proximal colon
326 and 6 for distal colon).

327

328 **Continual exposure to DCA potentiated mechanosensitivity of HT spinal afferents**
329 **independent of 5-HT**

330 Our next series of experiments examined the effect of DCA on afferent nerve
331 mechanosensitivity. A representative trace in Fig. 4A illustrated a time-dependent effect
332 of intraluminal administration of DCA (1 mM) on spinal afferent response to distention
333 in mouse distal colon. DCA did not change the overall afferent nerve response to
334 distention after 10 minutes of perfusion (Fig. 4B, $P=0.225$, two-way ANOVA with
335 Bonferroni test, $N=7$, although $P<0.05$ at 10 and 20 mmHg), but significantly
336 potentiated the distention response after 30 minutes of perfusion ($P<0.05$ for overall
337 response, $P<0.001$ for all pressure points). This potentiation was selective for HT
338 afferents ($P<0.05$, two-way ANOVA with Bonferroni test, $n=9$, $P<0.05$ at 20 and 40
339 mmHg, $P<0.01$ at 30, 50 and 60 mmHg), whereas there was no effect on LT afferents
340 ($P=0.372$, $n=12$). In a few recordings we recorded as long as 50 minutes and this
341 potentiation appeared to persist. Interestingly, following DCA application 6 out of 11
342 HT units were now activated at pressures <15 mmHg (i.e. behaved like a LT unit). This
343 increased mechanosensitivity after 30 minutes DCA perfusion was not affected by pre-
344 treatment with granisetron (Fig. 4C, $P<0.05$, two-way ANOVA with Bonferroni test,
345 $N=7$, $P<0.01$ at 20 mmHg, $P<0.05$ at 40 mmHg, $P<0.001$ at 50 and 60 mmHg). A lower
346 concentration of DCA at 100 μM was not able to potentiate mechanosensitivity (Fig. 4D,
347 $P=0.909$, $N=6$). However, bath application of this lower dose (100 μM) recapitulated
348 the sensitizing effect of intraluminal 1 mM DCA after only 10 minutes of perfusion (Fig.
349 4E, $P<0.05$ for overall response, $N=5$, $P<0.001$ at 60 mmHg). Changes in compliance,
350 the ability of a hollow organ to distend and increase volume with increasing pressure,
351 may influence afferent nerve sensitivity to distention (30). By comparing pressure-
352 volume curves, compliance was slightly increased after 30-minute intraluminal
353 perfusion of 100 μM DCA ($P<0.01$, two-way ANOVA) whereas no change was

354 observed in the other 3 groups, suggesting that the change in mechanosensitivity is
355 independent of compliance.

356

357 **DCA increased the excitability of DRG neurons but decreased the excitability of**
358 **NG neurons**

359 Differences observed in the role of 5-HT in afferent nerve signalling by DCA in the
360 proximal and distal colon may reflect differences in the innervation of these regions by
361 spinal and vagal afferents. Therefore, in perforated patch clamp recordings we
362 compared the effect of DCA on dissociated DRG and NG neurons. A brief superfusion
363 (10 min) of DCA at 100 μ M decreased the rheobase (i.e. increased the excitability) of
364 DRG neurons (Fig. 5A, $P < 0.01$, paired t-test, $n = 11$). Conversely, DCA increased the
365 rheobase (i.e. decreased the excitability) of NG neurons (Fig. 5B, $P < 0.01$, paired t-test,
366 $n = 12$). DCA also had opposing effects on the resting membrane potential; the resting
367 membrane potential of DRG neurons was depolarized after DCA application (Fig. 5C,
368 $P < 0.05$, paired t-test, $n = 11$), whereas the resting membrane potential of NG neurons
369 became hyperpolarized (Fig. 5D, $P < 0.01$, paired t-test, $n = 12$). However, input resistance
370 was not significantly changed in both DRG (1509 ± 244 vs. 2091 ± 447 $M\Omega$, $P = 0.142$,
371 paired t-test, $n = 11$) and NG neurons (746 ± 92 vs. 708 ± 101 $M\Omega$, $P = 0.796$, paired t-test,
372 $n = 11$). Vehicle superfusion (external solution, 10 min) had no effect on any of the
373 parameters measured above.

374

375 **Discussion**

376 Bile acids are increasingly recognized as important signalling molecules in the GI tract.
377 While excess bile acids within the colon are known to increase secretion and transit,
378 there has been little study of their impact on extrinsic sensory nerves innervating this
379 region of the gut, which could have important implications for nociceptive signalling.
380 The current study revealed different mechanisms underlying activation of vagal and
381 spinal afferents innervating mouse colon by the major colonic bile acid, deoxycholic
382 acid, at the level of nerve terminals compared to their neuronal cell bodies. DCA excited
383 spinal afferents directly, and to a lesser extent, via 5-HT release. In contrast, the
384 activation of vagal afferent pathways appears to depend on mucosal 5-HT release, as
385 direct administration of DCA to nodose ganglion neurons inhibited their excitability.
386 Interestingly, a longer exposure to DCA potentiated the mechanosensitivity of high
387 threshold spinal afferents, which are thought to be nociceptors (6), implying that bile
388 acids have the potential to evoke visceral hypersensitivity.

389

390 We identified that DCA activates extrinsic afferent nerves by both direct and indirect
391 mechanisms with the predominant mechanism differing between regions of the colon.
392 Bath application of DCA increased baseline firing frequency; this effect was unaltered
393 in the presence of 5-HT₃ receptor antagonist. This, combined with the almost immediate
394 increase in firing frequency upon DCA application, strongly suggests that it's the result
395 of direct activation of nerve terminals by DCA. Our patch clamp recording experiments
396 confirmed direct activation of DRG neurons by DCA. Conversely, granisetron reduced
397 the response to DCA applied through the colonic lumen suggesting an indirect
398 activation of 5-HT₃ receptors on nerve terminals by 5-HT, which may be released from

399 enterochromaffin cells via a TGR5 dependent mechanism (2). However, the effect of
400 granisetron was much greater in the proximal colon where it significantly blocked the
401 afferent response to intraluminal DCA. This difference may be explained in part by our
402 observation of lower EC cell density and lower absolute 5-HT release in the distal colon
403 upon DCA stimulation compared to the proximal colon. Moreover, while spinal
404 afferents are activated by 5-HT via 5-HT₃ receptors (20), previous work has shown
405 greater 5-HT_{3a} receptor subunit transcript expression on microarray in NG neurons
406 compared to DRG neurons (32) and thus there may be more 5-HT₃ receptor expression
407 in the proximal colon as it is innervated by both vagal and spinal afferent nerves
408 compared to the distal colon, which has predominant spinal afferent nerve innervation.
409 Thus, the smaller inhibition by granisetron on excitation by DCA on distal colon
410 afferent nerves may result from both less 5-HT release from the epithelium and lower 5-
411 HT₃ expression on afferent nerves in this region. Bile acids may also promote release
412 of other mediators from enteroendocrine cells such as glucagon-like peptide-1 (GLP-1)
413 (8, 23, 41). While GLP-1 is able to activate vagal afferents (14), previous studies did not
414 find a direct activation on DRG neurons (3) and clinical data suggests it may reduce
415 pain (19). Thus, a role for bile acid induced release and modulation of colonic afferents
416 for other enteroendocrine mediators requires further study. Bile acids may also promote
417 peristalsis either via 5-HT release to activate 5-HT₄ receptors on intrinsic afferents or by
418 directly activating enteric neurons (2, 7). Although peristalsis activates muscular
419 afferents (16), this would have little role in our experiments as they were performed in
420 the presence of the L-type calcium channel blocker nifedipine and muscarinic receptor
421 antagonist atropine to suppress smooth muscle activity. Although a variety of 5-HT
422 receptor subtypes are expressed in the gut, in the context of sensory signalling, most

423 attention has focused on 5-HT₃ and 5HT₄ receptors (15). Unlike the high abundance of
424 mRNA for 5-HT₃ receptor, 5-HT₄ receptor expression was low in both NG and DRG
425 neurons. A 5-HT₄ receptor agonist had no effect on the gastric vagal afferent activity
426 (43). In the colon, a 5-HT₄ agonist inhibited visceral hypersensitivity, although it was
427 not clear whether this was due to a direct action on nociceptive nerves (21). Conversely,
428 5-HT₃ receptor agonists directly excite distal colonic afferent nerves (20). Thus, while
429 we cannot exclude a role of other 5-HT receptor subtypes, we focused on 5-HT₃
430 receptors in the current study. Taken together, our results suggest that DCA activates
431 colonic afferents predominantly via release of 5-HT in the proximal colon whereas it
432 has both a 5-HT mediated activation and a direct activation of the extrinsic afferents in
433 the distal colon.

434

435 Since the distal colon is predominantly innervated by spinal afferents (6), some of
436 which are putative nociceptors, effect of DCA on mechanosensitivity was examined in
437 the distal colon. A brief intraluminal exposure to DCA did not alter mechanosensitivity
438 whereas a longer exposure (30 min) selectively sensitized high threshold spinal
439 afferents to mechanical stimulation. This was only observed at a concentration of 1mM
440 intraluminally, whereas bath application of a lower concentration quickly increased the
441 distention response. This suggests that DCA directly increases the mechanosensitivity
442 of spinal afferents but higher concentrations within the lumen are required. This effect
443 of the higher concentration within the lumen might be analogous to increased bile acid
444 delivery in the colon in a subpopulation of IBS patients (4, 34, 39). It has been
445 estimated that DCA 100 μ M is within the physiological range in the colon whereas
446 1mM may be pathophysiological as has been observed in disorders such as IBS (2, 17,

447 39). This is consistent with an *in vivo* study that DCA (4 mM) instillation into the rat
448 colon daily for 3 days induces increased visceromotor response to noxious colorectal
449 distention (42). Additionally, a recent study using an *in vitro* mouse colorectal
450 preparation revealed that 67% of mechanical insensitive afferents acquire
451 mechanosensitivity after a 5-min exposure to 0.5% bile salts (12). Our study showed
452 that the sensitizing effect of DCA on mechanosensitivity was not affected by
453 granisetron, suggesting a mechanism independent of mucosal 5-HT release.
454 Additionally, our patch clamp results revealed increased excitability of cultured DRG
455 neurons following exposure to DCA, strengthening the contention that direct
456 sensitization of DRG neurons by DCA is at least one of the underlying mechanisms of
457 the observed increased mechanosensitivity. The cellular mechanisms of this increased
458 mechanosensitivity such as the involvement of the transient receptor potential ankyrin 1
459 (TRPA1) channel that may be sensitized via $G_{\beta\gamma}$, protein kinase C and Ca^{2+} following
460 TGR5 activation (27) require further study.

461

462 A definitive distinction between vagal versus spinal afferent units within a given
463 recording in the proximal colon is not possible with our extracellular recordings, and
464 thus we performed patch clamp recordings to examine the direct effect of DCA on these
465 two neural populations. While we did not perform retrograde labelling to specifically
466 identify colon-projecting neurons, previous studies have shown sensory neurons,
467 including small diameter DRG neurons recorded in this study, express TGR5 (1). Our
468 finding that the excitability of unlabelled NG and DRG neurons is affected by DCA
469 suggests that TGR5 expression is not limited to gut-projecting afferent neurons.
470 Interestingly, in contrast with DRG neurons DCA inhibited the excitability of NG

471 neurons. This difference in the effect of DCA on the excitability is in keeping with
472 distinct gene expression profiles (e.g. ion channels) between DRG and NG neurons (32),
473 although specific channels and mechanisms involved require future study. The
474 inhibition of NG neurons by DCA is consistent with an *in vivo* study showing that
475 glycocholic acid decreases gastric vagal afferent response to distention at neutral pH
476 (22). Since a major function of vagal afferents in the GI tract is transmission of meal-
477 related satiety signals to the brain, the effect of DCA on vagal afferent excitability,
478 together with its effects on stimulating GLP-1 and 5-HT release, satiety mediators that
479 can activate vagal afferents (45), may suggest implications for satiety regulation.

480

481 FXR and TGR5 are the two most studied bile acid receptors. FXR is highly expressed in
482 the liver and ileum (10), with no evidence of its presence in the primary sensory
483 neurons. Since FXR is a nuclear receptor that fulfils bile acids' regulative roles at a
484 transcriptional level, it is unlikely to be involved in the current study, given the relative
485 short-term treatment of DCA. TGR5 is widely expressed, including in DRG neurons (1)
486 and enterochromaffin cells (2), and a key mediator of many rapid physiological and
487 pathophysiological effects of bile acids (7). Furthermore, FXR is activated mainly by
488 primary bile acids, whereas the most potent activators for TGR5 are secondary bile
489 acids (44). As such, the effects of DCA on colonic primary afferent signalling observed
490 in this study are likely mediated via TGR5. However, due to lack of specific
491 pharmacological tools, the present study did not directly address the involvement of
492 TGR5.

493

494 In conclusion, this study has elucidated different mechanisms underlying activation of
495 spinal and vagal afferents innervating mouse colon by the major secondary bile acid
496 DCA, and provided evidence that it can induce visceral hypersensitivity. The findings
497 of this study have important implications for studying mechanisms related to pain
498 signalling in GI disorders such as IBS.
499

500 **Acknowledgments**

501 We wish to thank Iva Kosatka for her outstanding technical assistance.

502

503 **Funding:** This study was supported by grants from Women's Giving Circle,

504 Department of Medicine of Queen's University.

505 **Conflict of interest:** Authors declare no conflict of interest.

506

507 **Author contribution:**

508 • DR obtained funding and supervised the project.

509 • DR, YY, EV and AL designed the study.

510 • YY, EV, SP, CB, CK and DG acquired, analysed and interpreted the data.

511 • YY, EV, AL and DR drafted and revised the manuscript.

512

513

514

515

References

- 516
517
518 1. **Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M,**
519 **Nassini R, Materazzi S, Guerrero-Alba R, Valdez-Morales E, Cottrell GS, Schoonjans K,**
520 **Geppetti P, Vanner SJ, Bunnett NW, and Corvera CU.** The TGR5 receptor mediates bile
521 acid-induced itch and analgesia. *J Clin Invest* 123: 1513-1530, 2013.
- 522 2. **Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW,**
523 **and Corvera CU.** The Receptor TGR5 Mediates the Prokinetic Actions of Intestinal Bile Acids
524 and Is Required for Normal Defecation in Mice. *Gastroenterology* 144: 145-154, 2013.
- 525 3. **Anand U, Yiangou Y, Akbar A, Quick T, MacQuillan A, Fox M, Sinisi M, Korchev**
526 **YE, Jones B, Bloom SR, and Anand P.** Glucagon-like peptide 1 receptor (GLP-1R) expression
527 by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. *PLoS*
528 *one* 13: e0198024, 2018.
- 529 4. **Bajor A, Tornblom H, Rudling M, Ung KA, and Simren M.** Increased colonic bile
530 acid exposure: a relevant factor for symptoms and treatment in IBS. *Gut* 64: 84-92, 2015.
- 531 5. **Bertrand PP.** Real-time measurement of serotonin release and motility in guinea pig
532 ileum. *J Physiol* 577: 689-704, 2006.
- 533 6. **Beyak MJ, Bulmer DCE, Jiang W, Keating C, Rong W, and Grundy D.** Extrinsic
534 sensory afferent nerves innervating the gastrointestinal tract. In: *Physiology of the*
535 *Gastrointestinal Tract*, edited by Johnson LR. Burlington: Elsevier Academic Press, 2006, p.
536 685-726.
- 537 7. **Bunnett NW.** Neuro-humoral signalling by bile acids and the TGR5 receptor in the
538 gastrointestinal tract. *J Physiol* 592: 2943-2950, 2014.
- 539 8. **Christiansen CB, Trammell SAJ, Wewer Albrechtsen NJ, Schoonjans K,**
540 **Albrechtsen R, Gillum MP, Kuhre RE, and Holst JJ.** Bile acids drive colonic secretion of
541 glucagon-like-peptide 1 and peptide-YY in rodents. *Am J Physiol Gastrointest Liver Physiol*
542 2019.
- 543 9. **Daly DM, Park SJ, Valinsky WC, and Beyak MJ.** Impaired intestinal afferent nerve
544 satiety signalling and vagal afferent excitability in diet induced obesity in the mouse. *J Physiol*
545 589: 2857-2870, 2011.
- 546 10. **De Magalhaes Filho CD, Downes M, and Evans RM.** Farnesoid X Receptor an
547 Emerging Target to Combat Obesity. *Dig Dis* 35: 185-190, 2017.
- 548 11. **Feng B, Brumovsky PR, and Gebhart GF.** Differential roles of stretch-sensitive
549 pelvic nerve afferents innervating mouse distal colon and rectum. *Am J Physiol Gastrointest*
550 *Liver Physiol* 298: G402-409, 2010.
- 551 12. **Feng B, Joyce SC, and Gebhart GF.** Optogenetic activation of mechanically
552 insensitive afferents in mouse colorectum reveals chemosensitivity. *Am J Physiol Gastrointest*
553 *Liver Physiol* 310: G790-798, 2016.
- 554 13. **Freeling JL, and Rezvani K.** Assessment of murine colorectal cancer by micro-
555 ultrasound using three dimensional reconstruction and non-linear contrast imaging. *Mol Ther-*
556 *Meth Clin D* 3: 2016.

- 557 14. **Gaisano GG, Park SJ, Daly DM, and Beyak MJ.** Glucagon-like peptide-1 inhibits
558 voltage-gated potassium currents in mouse nodose ganglion neurons. *Neurogastroenterol Motil*
559 22: 470-479, e111, 2010.
- 560 15. **Grundy D.** 5-HT system in the gut: roles in the regulation of visceral sensitivity and
561 motor functions. *Eur Rev Med Pharmacol Sci* 12 Suppl 1: 63-67, 2008.
- 562 16. **Grundy D.** What activates visceral afferents? *Gut* 53: ii5-ii8, 2004.
- 563 17. **Hamilton JP, Xie G, Raufman JP, Hogan S, Griffin TL, Packard CA, Chatfield**
564 **DA, Hagey LR, Steinbach JH, and Hofmann AF.** Human cecal bile acids: concentration and
565 spectrum. *Am J Physiol Gastrointest Liver Physiol* 293: G256-263, 2007.
- 566 18. **Hegy P, Maleth J, Walters JR, Hofmann AF, and Keely SJ.** Guts and Gall: Bile
567 Acids in Regulation of Intestinal Epithelial Function in Health and Disease. *Physiol Rev* 98:
568 1983-2023, 2018.
- 569 19. **Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, and Schambye H.**
570 Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in
571 patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.
572 *Aliment Pharmacol Ther* 29: 198-206, 2009.
- 573 20. **Hicks GA, Coldwell JR, Schindler M, Ward PA, Jenkins D, Lynn PA, Humphrey**
574 **PP, and Blackshaw LA.** Excitation of rat colonic afferent fibres by 5-HT(3) receptors. *J*
575 *Physiol* 544: 861-869, 2002.
- 576 21. **Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, Brooks EM,**
577 **Zhao H, Swain GM, Moses PL, Galligan JJ, Sharkey KA, Greenwood-Van Meerveld B,**
578 **and Mawe GM.** Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive
579 motility and inhibits visceral hypersensitivity. *Gastroenterology* 142: 844-854 e844, 2012.
- 580 22. **Kang YM, Bielefeldt K, and Gebhart GF.** Sensitization of mechanosensitive gastric
581 vagal afferent fibers in the rat by thermal and chemical stimuli and gastric ulcers. *J*
582 *Neurophysiol* 91: 1981-1989, 2004.
- 583 23. **Katsuma S, Hirasawa A, and Tsujimoto G.** Bile acids promote glucagon-like
584 peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. *Biochemical*
585 *and Biophysical Research Communications* 329: 386-390, 2005.
- 586 24. **Keating C, Nocchi L, Yu Y, Donovan J, and Grundy D.** Ageing and gastrointestinal
587 sensory function: altered colonic mechanosensory and chemosensory function in the aged
588 mouse. *J Physiol* 594: 4549-4564, 2016.
- 589 25. **Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, and Pfragner R.** Luminal
590 regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts,
591 amines, tastants, and olfactants. *Am J Physiol-Gastr L* 295: G260-G272, 2008.
- 592 26. **Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, and**
593 **Keely SJ.** Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human
594 beta-defensin-1 and -2 secretion by colonic epithelial cells. *FASEB J* 31: 3848-3857, 2017.
- 595 27. **Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, McIntyre P, Bron R,**
596 **Wilson YM, Krappitz M, Haerteis S, Korbmacher C, Steinhoff MS, Nassini R, Materazzi**

- 597 **S, Geppetti P, Corvera CU, and Bunnett NW.** The bile acid receptor TGR5 activates the
598 TRPA1 channel to induce itch in mice. *Gastroenterology* 147: 1417-1428, 2014.
- 599 28. **Malin SA, Christianson JA, Bielefeldt K, and Davis BM.** TPRV1 expression defines
600 functionally distinct pelvic colon afferents. *J Neurosci* 29: 743-752, 2009.
- 601 29. **Mertens KL, Kalsbeek A, Soeters MR, and Eggink HM.** Bile Acid Signaling
602 Pathways from the Enterohepatic Circulation to the Central Nervous System. *Front Neurosci* 11:
603 617, 2017.
- 604 30. **Notivol R, Coffin B, Azpiroz F, Mearin F, Serra J, and Malagelada JR.** Gastric tone
605 determines the sensitivity of the stomach to distention. *Gastroenterology* 108: 330-336, 1995.
- 606 31. **Payne CM, Bernstein C, Dvorak K, and Bernstein H.** Hydrophobic bile acids,
607 genomic instability, Darwinian selection, and colon carcinogenesis. *Clin Exp Gastroenterol* 1:
608 19-47, 2008.
- 609 32. **Peeters PJ, Aerssens J, de Hoogt R, Stanisz A, Gohlmann HW, Hillsley K,
610 Meulemans A, Grundy D, Stead RH, and Coulie B.** Molecular profiling of murine sensory
611 neurons in the nodose and dorsal root ganglia labeled from the peritoneal cavity. *Physiological
612 genomics* 24: 252-263, 2006.
- 613 33. **Peiris M, Hockley JR, Reed DE, Smith ESJ, Bulmer DC, and Blackshaw LA.**
614 Peripheral KV7 channels regulate visceral sensory function in mouse and human colon. *Mol
615 Pain* 13: 1744806917709371, 2017.
- 616 34. **Peleman C, Camilleri M, Busciglio I, Burton D, Donato L, and Zinsmeister AR.**
617 Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel
618 Syndrome-Diarrhea Without Bile Acid Malabsorption. *Clin Gastroenterol Hepatol* 15: 720-727
619 e721, 2017.
- 620 35. **Peregrin AT, Ahlman H, Jodal M, and Lundgren O.** Involvement of serotonin and
621 calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin. *Br J
622 Pharmacol* 127: 887-894, 1999.
- 623 36. **Ponicke K, Gergs U, Buchwalow IB, Hauptmann S, and Neumann J.** On the
624 presence of serotonin in mammalian cardiomyocytes. *Mol Cell Biochem* 365: 301-312, 2012.
- 625 37. **Sanger GJ, and Nelson DR.** Selective and functional 5-hydroxytryptamine₃ receptor
626 antagonism by BRL 43694 (granisetron). *Eur J Pharmacol* 159: 113-124, 1989.
- 627 38. **Sessenwein JL, Baker CC, Pradhananga S, Maitland ME, Petrof EO, Allen-Vercoe
628 E, Noordhof C, Reed DE, Vanner SJ, and Lomax AE.** Protease-Mediated Suppression of
629 DRG Neuron Excitability by Commensal Bacteria. *J Neurosci* 37: 11758-11768, 2017.
- 630 39. **Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D,
631 Lueke A, Saenger A, Girtman A, and Zinsmeister AR.** Bowel functions, fecal unconjugated
632 primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.
633 *Clin Gastroenterol Hepatol* 11: 1270-1275 e1271, 2013.
- 634 40. **Su X, and Gebhart GF.** Mechanosensitive pelvic nerve afferent fibers innervating the
635 colon of the rat are polymodal in character. *J Neurophysiol* 80: 2632-2644, 1998.

- 636 41. **Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A,**
637 **Yamamoto H, Mataka C, Pruzanski M, Pellicciari R, Auwerx J, and Schoonjans K.** TGR5-
638 mediated bile acid sensing controls glucose homeostasis. *Cell Metab* 10: 167-177, 2009.
- 639 42. **Traub RJ, Tang B, Ji Y, Pandya S, Yfantis H, and Sun Y.** A rat model of chronic
640 postinflammatory visceral pain induced by deoxycholic acid. *Gastroenterology* 135: 2075-2083,
641 2008.
- 642 43. **Uneyama H, Nijima A, Tanaka T, and Torii K.** Receptor subtype specific activation
643 of the rat gastric vagal afferent fibers to serotonin. *Life Sci* 72: 415-423, 2002.
- 644 44. **Wahlstrom A, Sayin SI, Marschall HU, and Backhed F.** Intestinal Crosstalk between
645 Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metabolism* 24: 41-50,
646 2016.
- 647 45. **Yu Y, Park SJ, and Beyak MJ.** Inducible nitric oxide synthase-derived nitric oxide
648 reduces vagal satiety signalling in obese mice. *J Physiol* 597: 1487-1502, 2019.
- 649
- 650

651 **Figure legends**

652 **Figure 1. DCA increased afferent firing frequency in mouse proximal and distal**
653 **colon.**

654 (A&C) DCA (100, 300 μ M and 1 mM) induced increased baseline firing frequency on
655 LT (A) and HT (C) afferents innervating proximal colon, one-way ANOVA with
656 Bonferroni test. (B&D) DCA (100 μ M and 1 mM) increased firing rate of LT (B) and
657 HT (D) afferents innervating distal colon. (E&F) The number of LT and HT afferents
658 responding to DCA (1mM) in the proximal and distal colon. N=10 for proximal colon;
659 N=6 for distal colon. LT, low threshold; HT, high threshold.

660

661 **Figure 2. Intraluminal administration of DCA activated afferent nerves indirectly**
662 **via 5-HT release.**

663 (A) Recording showing the response of an afferent nerve to bath and intraluminal
664 application of 1 mM DCA in a proximal colon preparation. (B) Pre-treatment with
665 granisetron (1 μ M) did not change afferent response to bath-applied DCA in the
666 proximal colon (paired t-test, N=5), regardless the order of treatments. (C) Granisetron
667 did not change afferent response to bath-applied DCA in the distal colon (N=5). (D)
668 Granisetron decreased afferent response to intraluminal application of DCA in the
669 proximal colon, regardless of the order of treatments ($P<0.01$, paired t-test, N=5). (E)
670 Granisetron did not significantly change afferent response to intraluminal administration
671 of DCA in the distal colon (paired t-test, N=8). (F) The percent inhibition on the
672 response to DCA by granisetron was lower in the distal colon compared to proximal
673 colon ($P<0.05$, unpaired t-test).

674

675 **Figure 3. DCA stimulated greater 5-HT release in the proximal colon.**

676 (A&B) 5-HT release during DCA incubation (1 mM, 10 min) was greater than basal
677 release (incubated in Krebs for 10 min) in both proximal ($P<0.05$, paired t-test, N=5)
678 and distal colon ($P<0.05$, N=5). (C) Basal 5-HT release was greater in the proximal
679 colon compared to the distal colon ($P<0.05$, unpaired t-test). (D) DCA stimulated 5-HT
680 release was also higher in the proximal colon ($P<0.05$). Fluoxetine (1 μ M) was present
681 in both basal and DCA conditions. The concentration of 5-HT was normalized to the
682 tissue weight. (E) Representative images showing 5-HT immunoreactivity in the
683 proximal and distal colon. Scale bar =50 μ m. (F) EC cell density was greater in the
684 proximal colon compared to the distal colon ($P<0.01$, unpaired t-test, N=5 for proximal
685 colon and 6 for distal colon).

686

687

688

689 **Figure 4. Continual exposure to DCA potentiated mechanosensitivity of HT spinal**
690 **afferents independent of 5-HT.**

691 (A) Representative trace showing afferent response to distention in the presence of DCA
692 (1 mM, intraluminal perfusion for 30 minutes) in mouse distal colon. (B) DCA did not

693 potentiate afferent response to distention until 30 minutes after perfusion, $P < 0.05$, two-
694 way ANOVA, $N = 7$. $P = 0.225$ for 10 min. Single unit analysis revealed that the main
695 effect was on HT afferents, $P < 0.05$. (C) This potentiation was not blocked by
696 granisetron ($1 \mu\text{M}$), $P < 0.05$. (D) A lower concentration ($100 \mu\text{M}$) did not cause any
697 potentiation to distension. (E) Bath application of $100 \mu\text{M}$ DCA for 10 minutes
698 increased afferent response to distension, $P < 0.05$.

699

700 **Figure 5. DCA increased excitability of DRG neurons whereas decreased**
701 **excitability of NG neurons.**







702 DCA superfusion ($100 \mu\text{M}$ for 10 minutes) decreased the rheobase in DRG neurons (A,
703 $P < 0.01$, paired t-test, $n = 11$) but increased the rheobase in NG neurons (B, $P < 0.01$,
704 $n = 12$). DCA depolarized resting membrane potential in DRG neurons (C, paired t-test,
705 $P < 0.05$) but hyperpolarized that in NG neurons (D, $P < 0.01$). Vehicle had no effect on
706 rheobase and resting membrane potential. DRG, dorsal root ganglion; NG, nodose
707 ganglion.







708








709 **Supplemental Material**






710 https://figshare.com/articles/supp_figure_DCA_AJP_pptx/8243252/1


711








A**B****C****D****E**





DCA (deoxycholic acid)
 EC (enterochromaffin)
 TGR5 (G protein-coupled bile acid receptor)